%0 Journal Article
%K Humans
%K Hypoglycemic Agents/adverse effects
%K *Diabetes Mellitus, Type 2/drug therapy
%K *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
%K *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
%K Glucagon-Like Peptide-1 Receptor/agonists
%K Cohort Studies
%K Sulfonylurea Compounds/adverse effects
%K *Pulmonary Disease, Chronic Obstructive/drug therapy
%B Bmj
%D 2022
%G eng
%M 36318979
%P e071380
%R 10.1136/bmj-2022-071380
%T Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study
%V 379
%2 PMC9623550 at https://www.icmje.org/disclosure-of-interest/ and declare: this study was funded by the Canadian Institutes of Health Research; LA has received consulting fees from Janssen and Pfizer unrelated to this project; SS has attended scientific advisory committee meetings for AstraZeneca, Atara, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer, and Seqirus and has received speaking fees from Boehringer-Ingelheim and Novartis; no other relationships or activities that could appear to have influenced the submitted work.
%7 2022/11/02
%@ 0959-8138 (Print)
0959-8138